Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis

Blood

Volumn 88, Issue 2, 1996, Pages 622-632

  McSweeney, P A ^a   Wells, D A ^b   Shults, K E ^b   Nash, R A ^b   Bensinger, W I ^b   Buckner, C D ^b   Loken, M R ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN;

ANEUPLOIDY; ARTICLE; B LYMPHOCYTE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029946705     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.2.622.bloodjournal882622     Document Type: Article

References (49)

1. Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD: Studies on the clonal origin of multiple myeloma: Use of individually specific (idiotype) antibodies trace the oncogenic event to its earliest point of expression in B cell differentiation. J Exp Med 150:792, 1979
2. Caligaris-Cappio F, Bergui L, Pizzola TG, Malavasi F, Chilosi M, Campani D, Van Camp B, Janossy G: Identification of malignant plasma cells precursors in the bone marrow of multiple myeloma. J Clin Invest 76:1243, 1985
3. Epstein J, Barlogie B, Katzmann J, Alexanian R: Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood 71:861, 1988
4. Pilarski LM, Jensen GS: Monoclonal circulating B cells in multiple myeloma: A continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 6:297, 1992
5. + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711, 1991
6. + peripheral blood cells expressing CD38, CD56 and monotypic Ig light chain. Blood 85:436, 1995
7. Chiu EKW, Ganeshaguru K, Hoffbrand AV, Mehta AB: Circulating monoclonal B lymphocytes in multiple myeloma. Br J Haematol 72:28, 1989
8. Berenson J, Wong R, Kim K, Brown N, Lichenstein A: Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 70:1550, 1987
9. Takishita M, Kosaka M, Goto T, Saito S. Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies. Br J Haematol 87:735, 1994
10. Terstappen LWMM, Johnsen S, Segers-Nolten IMJ, Loken MR: Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 76:1739, 1990
11. Latreille J, Barlogie B, Diosik G, Drewinko B, Alexanian R: Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 61:929, 1982
12. Terstappen LWMM, Loken MR: Leukocyte differential counting, in Laerum OD (ed): Flow Cytometry in Hematology. New York, NY, Academic, 1992
13. Krishan AJ: Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. Cell Biol 66:188, 1975
14. Orfao A, Garcia-Sanz R, Lopez-Berges MC, Belen Vidriales M, Gonzalez M, Caballero MD, San Miguel JF. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 17:332, 1994
15. Garcia-Sanz R, Orfao A, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 90:106, 1995
16. Terstappen LWMM, Shah VO, Civin CI, Hurwitz CA, Loken MR: Multidimensional flow cytometry as a new approach for discrimination between normal and leukemic cells in peripheral blood and bone marrow. Prog in Cytometry, Reports from the Cytometry Users Conference, Ghent, Belgium, 1989, p 4
17. Stelzer GT, Shults KE, Loken MR: CD45 Gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 677:265, 1993
18. Gohde W, Schumann J, Buchner T, Otto F, Barlogie B: Pulse cytophotometry: Application in tumor cell biology and clinical oncology, in Melamed MR, Mullaney PF, Mendelsohn ML (eds): Flow Cytometry and Sorting. New York, NY, Wiley, p 716, 1979
19. Stelzer GT, Shults KE, Wormsley SB, Loken MR: Detection of occult lymphoma cells in bone marrow aspirates by multi-dimensional flow cytometry. Prog Clin Biol Res 337:629, 1992
20. Loken MR, Shah VO, Datilia KL, Civin CI: Flow cytometric analysis of human bone marrow: II. Normal B lymphoid development. Blood 70:1316, 1987
21. Epstein J, Xiao H, He X-Y: Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 322:664, 1990
22. Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI: Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 72:299, 1988
23. Duperray C, Bataille R, Boiron JM, Haagen IA, Cantaloube JF, Zhang XG, Boucheix C, Klein B: No expansion of pre-B and B-cell compartments in the bone marrow of multiple myeloma. Cancer Res 51:3224, 1991
24. Tienhaara A, Pelliniemi TT: Peripheral blood lymphocytes in multiple myeloma. Acta Haematol 91:57, 1994
25. Levy Y, Schmitt C, Tsapis A, Brouet JC, Fermand JP: Phenotype and immunoglobulin gene configuration of blood B cells from patients with multiple myeloma. Clin Exp Immunol 84:435, 1991
26. Clofent G, Klein B, Commes T, Ghanem N, Lefranc MP, Bataille R: No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol 71:357, 1989
27. Baldini L, Cro L, Delia D, Chioboli O, Neri A, Maiolo AT: Analysis of tumor-specific immunoglobulins gene rearrangements in peripheral blood B-cells of multiple myeloma patients. Am J Hematol 37:1, 1991
28. Commes T, Clofent G, Ghanem N, Zhang XG, Lefranc MP, Bataille R, Klein B: Analysis of the B-cell compartment in plasma cell leukemia and multiple myeloma: Immunoglobulin gene rearrangement of EBV-infected B-cell lines. Leukemia 7:609, 1993
29. Billadeau D, Greipp P, Ahmann G, Witzig T, Van Ness B: Detection of B-cells clonally related to the tumor population in multiple myeloma and MGUS. Curr Top Microbiol Immunol 194:9, 1995
30. Ralph QM, Brisco MJ, Joshua D, Brown R, Gibson J, Morley AA: Advancement of multiple myeloma through plateau phase does not involve a new B-cell clone: Evidence from the Ig heavy chain gene. Blood 82:202, 1993
31. Sahota S, Oscier DG, Hamblin T, Stevenson FK: Assessment of the role of clonogenic B lymphocytes in the pathogenesis of multiple myeloma. Leukemia 8:1285, 1994
32. Vescio RA, Cao J, Hong CH, Kim A, Lee CC, Wu CH, Der Danielian M, Wu V, Newman R, Lichtenstein AK, Berenson JR: Myeloma Ig heavy V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 155:2487, 1995
33. Tonegawa S: Somatic generation of antibody diversity. Nature 302:575, 1983
34. Vescio RA, Hong CH, Cao J, Kim A, Schiller G, Lichtenstein AK, Berenson RH, Berenson JR: The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 84:3283, 1994
35. + is the common phenotype of myeloma cells. Ann Hematol 64:132, 1992
36. Van Camp B, Dune BG, Spier C, Dewaele M, Van Riet I, Vela E, Frutiger Y, Richter, Grogan TM: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 76:377, 1990
37. Drach J, Gattringer C, Huber H: Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol 83:418, 1991
38. Kozbor D, Moretta A, Messner HA, Moretta L, Croce CM: Tp44 molecules involved in antigen-indepedant T-cell activation are expressed at high level on human plasma cells. J Immunol 138:4128, 1987
39. Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M: Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood 84:2597, 1994
40. Berenson JR, Vescio RA, Hong CH, Cao J, Kim A, Lee CC, Schiller G, Berenson RH, Lichtenstein AK: Multiple myeloma clones are derived from a cell late in B lymphoid development. Curr Top Microbiol Immunol 194:17, 1995
41. Anderson KC: Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol 13:1291, 1995
42. Barlogie B, Jagannath S, Vesole D, Tricot G: Autologous and allogeneic transplants for multiple myeloma. Semin Hematol 32:31, 1995 (review)
43. Anderson K, Barut BA, Ritz J, Freedman AS, Takvorian T, Rabinowe SN, Soiffer R, Heflin L, Coral F, Dear K, Mauch P, Nadler L: Monoclonal antibody purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 77:712, 1991
44. Rhodes EG, Baker PK, Duguid JK, Davies JM, Rhodes JM: A method for purging of myeloma bone marrow using peanut agglutinin as an anti-plasma cell agent, in combination with CD19 monoclonal antibody. Bone Marrow Transplant 10:485, 1992
45. Stevenson FK, Bell AJ, Cusack R, Hamblin TJ, Slade CJ, Spellerberg MB, Stevenson T: Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77:1071, 1991
46. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC: Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma. Blood 84:3017, 1994
47. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A: High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596, 1995
48. Press O, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Mathews DC, Fisher LD, Bernstein ID: Radiolabelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219, 1993
49. 131I-labelled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122, 1995